Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birinapant - Medivir AB

Drug Profile

Birinapant - Medivir AB

Alternative Names: TL-32711

Latest Information Update: 10 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Princeton University
  • Developer Medivir AB; National Cancer Institute (USA); University of Pennsylvania
  • Class Amides; Antineoplastics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Hepatitis B; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Head and neck cancer
  • No development reported HIV infections; Legionella infections; Lymphoma; Pancreatic cancer; Tuberculosis

Most Recent Events

  • 03 Jun 2019 Additional efficacy results from phase I/II trial in Solid tumours were released by Medivir
  • 23 Jan 2019 National Cancer Institute plans a phase I trial for Squamous Cell Carcinoma of the head and neck (Second-line therapy or greater, recurrent) in USA (NCT03809208)
  • 07 Jan 2019 Phase-I clinical trials in Head and neck cancer (Second-line therapy or greater, Recurrent, Combination therapy) in USA (IV) (NCT03803774)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top